Advanced Biomed Inc. (ADVB) SEC Filings & Earnings Calls
EquiReason read 9 Advanced Biomed Inc. SEC filings in the last 12 months. Latest: 10-K on 2026-10-13 — Company completed strategic restructuring: sold biomedical operations, acquired Acellent, and shifted focus to AI financial verification, generating first revenue of $127,637..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 5.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 17 Nov, in 24 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
13 Oct 202610-KCompany completed strategic restructuring: sold biomedical operations, acquired Acellent, and shifted focus to AI financial verification, generating first revenue of $127,637.open
Figures in the filing · each found in the filing text
| Revenue · continuing_operations · FY2026 | $127637.00 | |
| Net loss from continuing operations · continuing_operations · FY2026 | $-6M | +476% y/y |
| Cash · continuing_operations · 2026-06-30 | $385535.00 | |
| Net cash used in operating activities - continuing operations · continuing_operations · FY2026 | $-961341.00 | -58% y/y |
| Employees · 2026-10-13 | 12 | |
| Gain on disposal of subsidiaries · discontinued_operations · FY2026 | $14M | |
| Provision for expected credit losses · continuing_operations · FY2026 | $3M |
Risks flagged
Limited revenue and profitability risk
“We have generated limited revenue from our AI-focused operations and may never achieve profitability.” · word for word
Liquidity risk
“As of June 30, 2026, we had cash of $385,535” · word for word
Credit risk from former subsidiaries
“Provision for expected credit losses 2,918,909” · word for word
Nasdaq compliance risk
“On July 18, 2025, we received a written notification from Nasdaq notifying us that we were not in compliance with the minimum bid price requirement” · word for word
30 Jun 20268-K · 1.01Advanced Biomed Inc. agrees to sell 100% of its Taiwan subsidiary for $490,000, divesting its biomedical R&D operations including the A+PerfusC platform.being acquiredopen
Figures in the filing · each found in the filing text
| Purchase price · Taiwan subsidiary · 2026-06-30 | $490000.00 |
Risks flagged
Sale of core R&D subsidiary may indicate financial distress or strategic pivot away from biomedical research.
“The Taiwan Subsidiary conducts the Company’s biomedical research and development operations” · word for word
4 Jun 2026DEF 14AAdvanced Biomed Inc. held its annual meeting proxy statement, disclosing a strategic pivot to AI via acquisition from its new CEO, no revenue, and a net loss of $3.26M.open
Risks flagged
No revenue / pre-revenue stage
“The Company had no revenues during fiscal years 2025 or 2024, and its net losses reflect operating expenses related to its clinical stage operations.” · word for word
Related party transaction risk
“On April 30, 2026, the Company completed the acquisition of Acellent Technologies (Hong Kong) Co. Limited ('Acellent') from Xiaomin Chen, our Chairman of the Board and Chief Executive Officer.” · word for word
15 May 202610-QAdvanced Biomed sold its Hong Kong subsidiary, acquired Acellent HK to pivot to AI-powered financial audit, and secured additional financing; still pre-revenue with going concern doubt.open
Figures in the filing · each found in the filing text
| Net income (loss) · Q3-2026 | $-488942.00 | |
| Net income (loss) · 9M-2026 | $6M | |
| Free cash flow · 9M-2026 | $-1M | |
| Operating cash flow · 9M-2026 | $-1M |
Risks flagged
Going concern uncertainty
“These conditions, among others, give rise to substantial doubt as to whether the Company will be able to continue as a going concern.” · word for word
No revenue generation
“Since our inception, we do not have any products approved for sale, we have not generated any revenue from the sale of products, and we do not expect to generate revenue from the sale of our product candidates until we complete clinical development, submit regulatory filings and receive approvals from the applicable regulatory bodies for such product candida” · word for word
Regulatory approval risk
“All of our products must be approved by applicable regulatory authorities before being sold to customers... Due to differences in regulatory and clinical registration requirements, we may not be able to obtain device and product approvals or provide product service on time.” · word for word
Strategic pivot execution risk
“The integration of Acellent HK facilitates the Company’s strategic pivot toward AI-powered financial audit solutions. ... the Company secured further liquidity to support its transition and general working capital needs.” · word for word
13 Feb 202610-QPre-revenue biotech company reports net income due to one-time gain from subsidiary sale, but continues to burn cash and faces going concern risk.open
Figures in the filing · each found in the filing text
| Net income (loss) · Q2-2026 | $7M | |
| Free cash flow · H1-2026 | $-1M | |
| Operating cash flow · H1-2026 | $-1M | |
| Price purchase · 2026-01-28 | $0.06 |
Risks flagged
Going concern risk
“These conditions give rise to substantial doubt as to whether the Company will be able to continue as a going concern.” · word for word
No revenue, pre-commercial stage
“we have not commenced sales of our products nor have any revenue-generating products” · word for word
Regulatory approval dependency
“All of our products must be approved by applicable regulatory authorities before being sold to customers.” · word for word
19 Nov 202510-QQ3 2025 net loss increased 46% YoY to $386.9k, with no product revenue and going concern risk.earningsopen
Figures in the filing · each found in the filing text
| Net loss · Q3-2025 | $-386901.00 | +46% y/y |
| Operating cash flow · Q3-2025 | $-610342.00 | |
| Free cash flow · Q3-2025 | $-612113.00 |
Risks flagged
Going concern risk
“These conditions give rise to substantial doubt as to whether the Company will be able to continue as a going concern.” · word for word
No revenue from products
“Since our inception, we do not have any products approved for sale, we have not generated any revenue from the sale of products” · word for word
Regulatory approval risk
“All of our products must be approved by applicable regulatory authorities before being sold to customers.” · word for word
Advanced Biomed Inc. — questions
- What did Advanced Biomed Inc. file recently?
- 9 SEC filings in the last 12 months. Latest: 10-K on 2026-10-13 — Company completed strategic restructuring: sold biomedical operations, acquired Acellent, and shifted focus to AI financial verification, generating first revenue of $127,637.
Every figure on this page comes from Advanced Biomed Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.